<DOC>
	<DOCNO>NCT02410473</DOCNO>
	<brief_summary>Neonates , child single ventricle congenital heart disease , undergo multiple complex cardiac surgery high risk increase perioperative blood loss , blood product transfusion . In addition , patient present increase risk postoperative thromboembolic complication . For long time , bleed management base empiric administration different blood product ( e.g . platelet concentrate , cryoprecipitates , and/or activate factor VII ) , topical hemostatic agent , surgical manipulation . Recently , use viscoelastic test ( e.g . thromboelastography ( TEG ) thromboelastometry ( ROTEM ) ) increase , allow well assessment perioperative coagulopathy , 'rational ' treatment bleeding . While TEG ROTEM record viscoelastic property whole blood measure mechanical impedance relate change clot formation , T2MR , miniaturize , magnetic resonance-based diagnostic platform , measure water molecule react presence magnetic field evaluate broad range hemostasis measurement . In study , prospectively collect demographic data , surgical characteristic , amount perioperative bleeding blood product transfusion , result laboratory assay , postoperative outcome ( 30-day follow-up discharge ) , aim ass current practice , develop algorithm-based approach administration target blood product pro-coagulant therapy . Our goal : reduction blood product utilization , reduction incidence massive bleeding postoperative thrombosis .</brief_summary>
	<brief_title>Evaluation Coagulation Testing Patients Undergoing Cardiac Surgery</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<criteria>Neonates infant patient ( 0 12 month age ) undergoing complex cardiac surgical procedure cardiac surgery patient &gt; 12 month age previously undergone 2 sternotomies child moribund condition ( American Society Anesthesiology ( ASA 5 ) child hematological and/or oncological disease Jehovah witness If child undergoing patent ductus arteriosus ( PDA ) ligation procedure consider risk thrombosis and/or bleed provide consent enrollment ( e.g . Ventricular Septal Defect repair )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Congenital Heart Disease</keyword>
	<keyword>Point-of-care coagulation monitoring</keyword>
</DOC>